As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
18 Analysts have issued a Voyager Therapeutics, Inc. forecast:
18 Analysts have issued a Voyager Therapeutics, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 31 31 |
81%
81%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -137 -137 |
919%
919%
|
|
| EBIT (Operating Income) EBIT | -141 -141 |
1,310%
1,310%
|
|
| Net Profit | -126 -126 |
587%
587%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Alfred Sandrock |
| Employees | 172 |
| Founded | 2013 |
| Website | www.voyagertherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


